Prepping a case for canakinumab, Novartis tries to stake out a high-value segment of huge cardio market
Novartis probably already has the data it needs for a regulatory approval of its big cardio drug canakinumab. Now it says it has the data …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
